Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 44,706

Document Document Title
WO/2018/010543A1
A complex disintegrant composition for oral solid preparation, comprising a disintegrant and a disintegrating aid, the disintegrant being a hygroscopic expansion type disintegrant, the disintegrating aid being a soluble small molecule su...  
WO/2018/011419A2
The invention relates to a uronic acid monomer for use in the treatment of immune system disturbances, inflammatory diseases, kidney diseases, allergies and neurodegenerative diseases, wherein the uronic acid monomer is α-L-guluronic ac...  
WO/2018/013870A1
Provided herein are combinations of (a) ceftibuten or a pharmaceutically acceptable salt thereof, or a hydrate of the foregoing; and (b) clavulanic acid, or a pharmaceutically acceptable salt thereof for use in a method of treating or pr...  
WO/2018/006643A1
Provided is a traditional Chinese medicine for providing a man with kidney-tonifying, blood circulation-promoting and liver-soothing benefits. The traditional Chinese medicine consists of the following raw materials: 15-25 g of Salvia mi...  
WO/2018/009424A1
The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.  
WO/2018/007878A1
Disclosed here is a novel use of a pharmaceutical composition comprising glutathione or its pharmaceutically acceptable salts or derivatives as active ingredient, in the forms of tablets, capsules, powder, spray and/or liquid, through or...  
WO/2018/008626A1
The purpose of the present invention is to provide a means for inhibiting renal hypofunction in a non-human animal. Provided is a method for inhibiting renal hypofunction in a non-human animal, said method comprising an administration st...  
WO/2018/003452A1
This kidney production method comprises: a step for tissue-specific removal of the metanephric mesenchyme of the metanephros of a non-human animal; a step of transplanting, in the metanephros, kidney precursor cells of non-human animal o...  
WO/2018/003899A1
The present invention pertains to a means and a method for ameliorating renal anemia. Specifically, the present invention pertains to a renal anemia-ameliorating composition that contains a lactic acid bacterium and/or a processed produc...  
WO/2018/003450A1
This organ production method comprises: a step for tissue-specific removal of a first portion of an organ of a non-human animal partway through the generation thereof; a step for transplanting, into the area from which the first portion ...  
WO/2018/003983A1
The invention provides a drug and a method for producing same, said drug having as an active ingredient a conjugate, in which an hANP peptide is bound to a sugar chain (N297 sugar chain) that binds to Asn 297 of an Fc-containing molecule...  
WO/2018/005356A1
Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and hetero...  
WO/2018/003451A1
This kidney production method comprises: a step for tissue-specific removal of the metanephric mesenchyme of the metanephros of a non-human animal; a step for transplanting human kidney precursor cells into the metanephros; and a step of...  
WO/2018/003997A1
The present invention addresses the problem of providing a safe and easy-to-prepare cell preparation for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell preparation for prevention and/or treatment...  
WO/2018/005177A1
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these co...  
WO/2018/005193A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2017/220488A1
The present invention is related to modified dextran conjugates, such as guanidine-dextran conjugates, comprising a PSMA binding tripeptide. The present invention further discloses a method for preparation of said conjugates as well as t...  
WO/2017/221142A1
The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also pr...  
WO/2017/221886A1
Provided are an intestinal environment-improving agent containing as an active ingredient a compound represented by formula [I] or a pharmaceutically acceptable salt thereof, and a novel medicine useful in the prevention or treatment of ...  
WO/2017/220042A2
Disclosed are an amrinone pharmaceutical composition and an application thereof in hypertension treatment. The amrinone pharmaceutical composition contains amrinone and a natural product compound (I) separated from dried blackberry lily ...  
WO/2017/217556A1
The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/...  
WO/2017/216165A1
The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate- degrading ba...  
WO/2017/211274A1
Provided are the use of lipids bearing fatty acids with an odd number of carbon atoms as pharmaceuticals or nutritional supplement. In particular, such lipids are used in the treatment and/or prevention of neurodegenerative diseases, opt...  
WO/2017/212273A1
The present invention provides co-crystals of glycopyrronium bromide with lactose. The glycopyrronium bromide and lactose in the novel co-crystals are present in a stoichiometric ratio of from about 1 :2 to 2: 1. These are characterized ...  
WO/2017/211248A1
Disclosed are a substituted imidazoquinazoline compound as represented by formula (I), and a pharmaceutical composition containing its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, isotopic variant, hydrate, ...  
WO/2017/209106A1
The present invention provides a novel oral composition of a single or twice daily dose type, which contains tipepidine or a pharmaceutically acceptable salt thereof, wherein the drug dissolution rate of tipepidine or the pharmaceuticall...  
WO/2017/209588A2
The present invention relates to a pharmaceutical composition in the form of a powder comprising amoxicillin, cineol and a pharmaceutically acceptable oil. The present formulation can also include clavulanic acid. The formulation is inte...  
WO/2017/206962A1
The present invention provides a novel inhibitor for FLT3 kinase, comprising a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an isomer, an ester, an acid, metabolite or a prodrug thereof. The pres...  
WO/2017/209267A1
The present invention provides a novel compound having a P2X3 and/or P2X2/3 receptor antagonistic activity. A compound represented by formula (I) (wherein R1a represents a substituted or unsubstituted alkyl group or the like; R1b represe...  
WO/2017/204318A1
Provided is a novel compound having an antagonism to P2X3 and/or P2X2/3 receptors. A compound represented by formula (I) [wherein: R1 represents an optionally substituted alkyl group, etc.; R2 represents an optionally substituted aromati...  
WO/2017/202365A1
Provided are a preparation method for a trifluoromethyl-substituted pyran derivative and an intermediate thereof, namely, a preparation method for a compound as shown in formula (I) and an intermediate thereof. The method is characterize...  
WO/2017/201684A1
A combination of external medicines of an active ingredient I applied to a lesion and an active ingredient II applied to both sides of the chest. The active ingredient I consists of an immune protein powder and a traditional Chinese medi...  
WO/2017/197789A1
A wolfberry and red ginseng liquor, the ingredient composition thereof being: 100g of fructus lycii, 80g of radix rehmanniae preparata, 30g of red ginseng, 20g of wolfiporia extensa, 70g of fallopia multiflora, 30g of polygonatum sibiric...  
WO/2017/197555A1
Provided are certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are described herein. The compounds or their pharmaceutically a...  
WO/2017/197784A1
A wolfberry and ginseng liquor, the ingredient composition thereof being: 220g of fructus lycii, 200g of radix rehmanniae, 100g of ophiopogon japonicus, 60g of apricot kernel, 50g of panax ginseng, 40g of wolfiporia extensa, 30g of angel...  
WO/2017/198205A1
The preparation method for the compound, composition and application thereof in preparing an angiotensin II receptor antagonist or application in preparing medicine for preventing and/or treating hypertension, chronic heart failure and d...  
WO/2017/197781A1
The present invention provides a health-care and body-strengthening Fructus Lycii liquor, comprising the following components: Fructus Lycii: 50 g; Flos Chrysanthemi: 50 g; Radix Rehmanniae Preparata: 45 g; stir-baked Massa Medicata Ferm...  
WO/2017/195804A1
Provided is a crystalline polymorph A of 15β-hydroxy-osaterone acetate having improved stabilities (storage stability, pulverization stability, and absorption property). Diffraction peaks characteristic of this crystalline polymorph A o...  
WO/2017/191114A1
The present invention relates to novel 5-(hydroxyalkyl)-1-heteroaryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compoun...  
WO/2017/191115A1
The present invention relates to novel Oxoalkyl-substituted 1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compoun...  
WO/2017/190568A1
Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl) methyl)-4-ethylb...  
WO/2017/193098A1
The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of ur...  
WO/2017/191117A1
The present invention relates to V1a receptor antagonists for use in the treatment and/or prevention of a renal disease, in particular of acute and chronic kidney disease. The invention furthermore relates to the use of arginine vasopres...  
WO/2017/191112A1
The present invention relates to novel 5-( fluoroalkyl)-1-aryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or ...  
WO/2017/191107A1
The present invention relates to novel 5-(carboxamide)-1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or...  
WO/2017/192930A1
The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and comp...  
WO/2017/192931A1
The invention provides substituted imidazo[1,2-α]pyridine compounds, substituted imidazo[1,2-α]pyrazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compos...  
WO/2017/191104A1
The invention relates to a novel and improved method for producing 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole-derivatives of the formula (I), in which R1A and R1B are selected independently of each other from the group comprising hydrogen,...  
WO/2017/191105A1
The present invention relates to novel 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or c...  
WO/2017/191638A1
The instant invention provides methods and compositions which are applicable for modulating, preventing or treating non-clinical and clinical conditions that are associated with composition of mammalian microbiome. Methods and compositio...  

Matches 1 - 50 out of 44,706